Free tools Windows power users keep installed
One-click scans. No signup required.
iTechGuides is reader-supported. When you buy through links on our site, we may earn an affiliate commission. As an Amazon Associate I earn from qualifying purchases. Learn more
A phosphorus(V) synthesis platform reported in 2021 gives researchers more control over the chemical links in an oligonucleotide strand. It can make several kinds of phosphate-backbone linkages—including versions with defined phosphorus stereochemistry—and combine them in one molecule. That could help drug designers explore new structures, but the study demonstrated a way to make molecules, not a more effective treatment or a gene therapy cure.
What makes an oligonucleotide unusual?
Oligonucleotides are short strands of DNA or RNA. Their sequence helps determine which biological target they recognize, but the chemical structure joining their building blocks can also affect properties relevant to a drug, including how it behaves in the body. The 2021 method focuses on those backbone links rather than changing the strand’s sequence.
| # | Preview | Product | Price | |
|---|---|---|---|---|
| 1 |
|
Molecular Biology of the Cell | $203.99 | Buy on Amazon |
| 2 |
|
Molecular Biology: Principles and Practice | $169.53 | Buy on Amazon |
| 3 |
|
Molecular Biology of the Cell | $160.49 | Buy on Amazon |
| 4 |
|
BRS Biochemistry, Molecular Biology, and Genetics (Board Review Series) | $64.99 | Buy on Amazon |
| 5 |
|
Molecular Cell Biology (842581) | $329.81 | Buy on Amazon |
In a typical phosphate linkage, phosphorus is connected to the neighboring building blocks through oxygen atoms. A phosphorothioate linkage replaces one non-bridging oxygen with sulfur. A phosphorodithioate has two such sulfur substitutions, while a phosphodiester retains the native oxygen-based linkage.
Recommended Free Tools
Phosphorothioate linkages can also differ in the three-dimensional configuration around phosphorus. A racemic preparation contains both configurations; a stereodefined preparation specifies one, such as the R or S form. That distinction gives researchers another structural variable to investigate.
#1 Best Overall
What does the phosphorus(V) method make possible?
Huang and colleagues described a phosphorus(V), or P(V), platform for making selected backbone linkages in DNA and other modified nucleotide polymers. Its reported options include stereodefined and racemic phosphorothioates, native phosphodiesters, and phosphorodithioates. Researchers can combine different linkage types at chosen positions to make chimeric oligonucleotides.
The significance is expanded synthetic access: scientists can test more combinations of linkage chemistry and placement in a strand. The paper presents this as a way to tune oligonucleotide designs, including antisense candidates. It does not show that a particular combination improves target recognition, drug exposure, safety, or clinical outcomes.
Rank #2
How does it compare with conventional synthesis?
Many established oligonucleotide processes use phosphorus(III), or P(III), phosphoramidite chemistry. The P(V) approach offers a different route and broader access to selected structures; it is not a blanket replacement for a mature method that already works well within its capabilities.
| Consideration | Established P(III) phosphoramidite chemistry | Reported P(V) platform |
|---|---|---|
| Phosphorus and reagent characteristics | Uses trivalent phosphorus building blocks. RNA-drug developer Punit Seth told Chemistry World that these reagents work well but are sensitive to water. | Uses phosphorus(V) chemistry; the study reports a standardized coupling protocol and stable reagents. |
| Control of phosphorothioate stereochemistry | Traditional phosphoramidite chemistry generally prepares phosphorothioates as mixtures of stereoisomers, according to Bristol Myers Squibb researcher Ivar McDonald. | Provides access to stereodefined phosphorothioates, including R and S configurations, as well as racemic products. |
| Reported linkage options | The comparison in the cited sources does not establish an equivalent range of interchangeable linkage types for this method. | Includes phosphorothioates, phosphodiesters, and phosphorodithioates, with selected combinations in chimeric strands. |
| Automation and conversion | Existing automation and established processes are part of the method’s maturity; the cited report does not give a comparable conversion time. | Chemistry World reported compatibility with automated protocols. In the study comparison it described, reactions reached full conversion in under two minutes; this is not a general timing guarantee for every synthesis. |
| Manufacturing maturity | Methods and supply chains are highly optimized and work well for existing applications, McDonald told Chemistry World. | Expands the available chemistry, but adoption requires validation and transition from established processes. |
What did the study demonstrate—and what remains unknown?
The primary paper describes a standardized coupling protocol and reports that the reagents are sustainably prepared and stable. Chemistry World’s contemporaneous coverage also reported automation compatibility and the study-specific conversion result above. These are synthesis and workflow findings, not evidence that medicines made with the platform are safe or effective.
Rank #3
The researchers’ rationale is that sequence and backbone chemistry can contribute differently to target recognition and pharmacokinetic properties. Establishing whether a new linkage pattern improves a candidate requires further work on the molecule and, ultimately, appropriate testing. The evidence here is a synthesis study, not a clinical trial.
Huang and colleagues’ 2021 introduction described more than 155 active clinical trials and multiple U.S. Food and Drug Administration approvals for therapeutic oligonucleotides, most containing modified phosphate linkages. That is a historical figure from the paper’s 2021 context, not a current trial count or evidence that this new platform produced an approved medicine.
Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.Why isn’t the new chemistry an immediate replacement?
Oligonucleotide manufacturing depends on reliable processes, instruments, quality controls, and supply chains. Existing P(III) chemistry is highly optimized, so a new method has to demonstrate not just access to interesting structures but also reproducibility and practical value in the relevant production setting.
Do these 3 things before closing this tab:
1Repair Windows errors before they cause bigger problems2Scan for outdated or missing drivers - takes under a minute3Clear out junk files and repair common Windows errorsMcDonald told Chemistry World that the team did not expect an overnight change because P(III) methods and supply chains were already highly optimized. The news report said the researchers were working with Millipore-Sigma in 2021 to make reagents commercially available. That historical report does not establish present-day availability or stock.
Best Value
What this could mean for gene-based drugs
The platform could broaden the set of oligonucleotide structures researchers can make and compare. That is a potentially useful medicinal-chemistry capability: it allows more deliberate investigation of where different phosphate linkages—and different phosphorus stereochemistry—might matter.
Whether those structures lead to better drugs is a separate question. The method itself is not gene therapy, does not demonstrate a cure, and does not establish clinical benefit. Its contribution is a broader synthesis toolkit for exploring candidate molecules.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
